Rigel Pharmaceuticals (RIGL) Return on Invested Capital (2024 - 2026)

Rigel Pharmaceuticals' Return on Invested Capital history runs 3 years deep, the most recent figure standing at 0.04% for Q1 2026.

• On a quarterly basis, Return on Invested Capital rose 2.0% year-over-year to 0.04% in Q1 2026; TTM through Mar 2026 was 0.04%, a 2.0% increase from a year earlier, with the FY2025 full-year figure at 0.2%, up 17.0% from the prior year.
• Return on Invested Capital eased to 0.04% in Q1 2026 per RIGL's latest filing, from 0.04% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.04% in Q4 2025 and bottomed at 0.01% in Q4 2024.
• The 3-year median for Return on Invested Capital is 0.03% (2025), against an average of 0.03%.
• Across the five-year window, Return on Invested Capital gained 3 bps in 2025 and climbed 2 bps in 2026, its largest moves.
• Year by year, Return on Invested Capital stood at 0.01% in 2024, then surged by 323 bps to 0.04% in 2025, then fell by 19 bps to 0.04% in 2026.
• Per Business Quant, the three latest RIGL Return on Invested Capital figures stand at 0.04% (Q1 2026), 0.04% (Q4 2025), and 0.02% (Q3 2025).